Rationale: Liver X receptors (LXRs) are oxysterol-activated nuclear receptors that are involved in the control of cholesterol homeostasis and inflammatory response. Human monocytes and macrophages express high levels of these receptors and are appropriate cells to study the response to LXR agonists. Objective: The purpose of this study was to identify new LXR targets in human primary monocytes and macrophages and the consequences of their activation. Methods and Results: We show that LXR agonists significantly increase the mRNA and protein levels of the retinoic acid receptor (RAR)␣ in primary monocytes and macrophages. LXR agonists promote RAR␣ gene transcription through binding to a specific LXR response element on RAR␣ gene promoter. Preincubation of monocytes or macrophages with LXR agonists before RAR␣ agonist treatment enhances synergistically the expression of several RAR␣ target genes. One of these genes encodes transglutaminase (TGM)2, a key factor required for macrophage phagocytosis. Accordingly, the combination of LXR and RAR␣ agonists at concentrations found in human atherosclerotic plaques markedly enhances the capabilities of macrophages to engulf apoptotic cells in a TGM2-dependent manner. Conclusions: These results indicate an important role for LXRs in the control of phagocytosis through an RAR␣-TGM2-dependent mechanism. A combination of LXR/RAR␣ agonists that may operate in atherosclerosis could also constitute a promising strategy to improve the clearance of apoptotic cells by macrophages in other pathological situations. (Circ Res. 2009;105:393-401.) 
L iver X receptors (LXRs) ␣ and ␤ are nuclear receptors activated by oxysterols. 1, 2 They control the expression of genes involved in lipid metabolism and inflammation. 3 LXR␣ is expressed primarily in liver, intestine, adipose tissue, and macrophages, whereas LXR␤ is widely expressed. 1, 2 Because LXRs, especially LXR␣, are present at high levels in macrophages, the effects of LXR activation or repression on macrophage functions have been widely investigated. 3, 4 Strong evidence suggests that LXRs are master regulators of cholesterol metabolism in these cells. LXR activation improves cholesterol homeostasis and stimulates cholesterol efflux through the coordinated regulation of apolipoprotein E and cholesterol transporters such as ABCA1 (ATP-binding cassette subfamily A member 1) and ABCG1 (ATP-binding cassette subfamily G member 1). [5] [6] [7] LXRs agonists also modulate the functions of macrophages in innate immunity and inflammation. Synthetic LXR agonists attenuate the inflammatory response of murine macrophages exposed to lipopolysaccharides 8 and increase macrophage survival in response to bacterial infection. 9 In humans, short-term exposure of macrophages to LXR agonists also reduces the inflammatory effects of lipopolysaccharides whereas longterm exposure increases macrophage response to lipopolysaccharides through Toll-like receptor 4 upregulation. 10 Macrophages come from the differentiation of peripheral blood monocytes, which are produced in the bone marrow by differentiation of stem cells, circulate in the blood Ϸ1 to 3 days, and then are recruited in tissues where they undergo differentiation. The role of LXRs has been less studied in monocytes than in macrophages but synthetic LXR agonists have recently been shown to reduce the inflammatory response of peripheral blood to lipopolysaccharides. 11 Here, we show that the nuclear receptor retinoic acid receptor (RAR)␣ is an LXR target gene in both human monocytes and macrophages. LXR agonists at concentrations found in the human atherosclerotic plaque enhance the transcriptional effects of RAR␣. One of the genes whose RAR␣-controlled transcription is increased on LXR stimulation encodes tissue transglutaminase (TGM)2. This effect results in a significant increase in the phagocytic capacity of human macrophages, which underlines the important role of LXRs in the modulation of macrophage phagocytosis.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Human peripheral blood monocytes were obtained from healthy donors, purified with the Monocyte Isolation Kit II (Miltenyi Biotec), and differentiated into macrophages with macrophagecolony stimulating factor. Mouse bone marrow-derived macrophages were collected from wild-type (WT) or LXR␣/␤ knockout (KO) mouse tibias and femurs. Microarray procedures were performed by Miltenyi Biotec; quantitative polymerase chain reaction (PCR) was performed by using a SYBR Green Real-time PCR kit (Invitrogen) on a LightCycler 2.0 detection system (Roche Diagnostics); chromatin immunoprecipitation was performed by using a ChIP-IT kit (Active Motif); and luciferase reporter assays were performed with the Dual Glo Luciferase Assay System (Promega). All-trans retinoic acid levels in human atherosclerotic plaques were determined by liquid chromatography-mass spectrometry (LC-MS). Phagocytosis was measured in macrophages incubated with 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester-stained apoptotic NB4 cells and analyzed with a LSRII flow cytometer (Becton Dickinson). Data are meansϮSD and Mann-Whitney U test was used to determine their significance.
Results

LXR␣ Activation Increases RAR␣ mRNA and Protein Levels in Primary Human Monocytes and Macrophages
We first treated primary human monocytes with 10 mol/L the LXR agonist T0901317 for 48 hours. Microarray exper-iments showed that among the nuclear receptor family, only 3 genes were significantly induced by LXR activation ( Figure  1A and Online Table I ). Two of them, namely LXR␣ (NR1H3) and peroxisome proliferator-activated receptor (PPAR)␥ (NR1C3), had already been described as LXR target genes. 12, 13 Expression of the third gene, RAR␣ (NR1B1), was induced by more than 2-fold in monocytes exposed to T0901317. Two other members of the RAR family, RAR␤ (NR1B2) and RAR␥ (NR1B3), remained unaffected ( Figure 1A ). Quantitative PCR analysis of primary human monocytes (Mo) demonstrated a reproducible 3-fold increase in RAR␣ mRNA levels on exposure to the LXR agonist ( Figure 1B a similar increase of RAR␣ mRNA level in differentiated macrophages (Mac) ( Figure 1B , bottom) and in a human monocytic cell line, THP-1 (not shown). A similar stimulation of RAR␣ gene transcription was detected in primary monocytes or macrophages treated for 24 hours with 1 or 10 mol/L GW3965, another LXR agonist, or with oxidized low-density lipoprotein, which contains natural LXR activators ( Figure 1C ). Importantly, the LXR agonistinduced increase in RAR␣ gene expression was also found at the protein level ( Figure 1D ). We also investigated the regulation of RAR␣ expression by LXR in mouse bone marrow-derived macrophages. On exposure to T0901317 for 24 hours, macrophages from WT mice demonstrated a significant induction of RAR␣ whose magnitude remained lower than in human macrophages (1.6-versus 3-fold induction; Figure 2A ). In macrophages from LXR␣/␤ double knockout, we confirmed the derepression of LXR target genes at basal state, 14 ie, RAR␣ and ABCA1 mRNA levels were 2-fold higher in untreated LXR␣/␤ KO than in WT mouse macrophages ( Figure 2A ). As expected, the LXR agonist had no effect on LXR␣/␤ KO macrophages. We then focused on human macrophages in which silencing of LXR␣ but not LXR␤ significantly reduced the expression of RAR␣ on exposure to T0901317 ( Figure  2B ). Altogether, these data identify RAR␣ as a new LXR␣ target in monocytes and macrophages.
LXRs Bind to a Specific LXR Response Element in the Human RAR␣ Promoter
Bioinformatic analysis of the promoter, as well as the first intron, of the human RAR␣ gene using MatInspector soft-ware identified 2 potential LXR response elements (LXREs) similar to the DR4 consensus sequence ( Figure 3A and Online Figure II ). 15 One was located between nucleotides Ϫ1242 to Ϫ1227 upstream of the transcription initiation site of RAR␣1 (P1), the other between nucleotides ϩ125 to ϩ139 downstream of transcription initiation site. The expression of RAR␣ in human is under control of at least 3 different promoters (Online Figure II) . 16 -18 LXRE1 and LXRE2 were located Ϫ10292 and Ϫ8926 bp upstream of promoter P1bis and Ϫ34124 to Ϫ32758 bp upstream of promoter P2, respectively. To obtain a direct evidence of in vivo binding of the LXR protein to these elements, we used a chromatin immunoprecipitation assay with 293T cells cotransfected with LXR␣/RXR␣ expression vectors and treated or not with 1 mol/L T0901317 for 90 minutes ( Figure 3B and 3C). After immunoprecipitation of the fragmented chromatin with an anti-LXR␣/␤ antibody, the genomic DNA region encompassing the LXRE1 could be amplified by PCR in T0901317treated cells, whereas no amplification products could be detected for LXRE2. Overall these data suggest that LXRE1 but not LXRE2 is a functional element in living cells. Interestingly, LXRE1 but not LXRE2 is conserved in the RAR␣ mouse promoter ( Figure 3A ).
LXR/RXR Heterodimers increase RAR␣ Promoter Activity
To test whether LXR␣/RXR␣ heterodimers activate the human RAR␣ promoter, we cloned a 1400-bp fragment upstream of the P1 promoter into the pGL3 luciferase reporter vector. As shown in Figure 3D , the activity of this promoter significantly increased in cells cotransfected with LXR␣ and RXR␣ expression vectors and then treated with 1 mol/L T0901317. This induction was abolished when the promoter was truncated at Ϫ1200 bp, thus lacking the LXRE, or when mutations were introduced in the LXRE element. Because the activity of the P1 promoter was weak under our experimental conditions and the corresponding mRNA only a minor RAR␣ isoform in human monocytes (Online Figure III) , we checked whether the LXRE1 site could also act as an enhancer of promoter P1bis activity. The transcriptional activity of the Ϫ640 bp promoter P1bis alone was unaffected by LXR␣/ RXR␣ cotransfection and T0901317 treatment. Addition of the LXRE1 site at the 5Ј end of the promoter enhanced the basal activity of this promoter construction (Online Figure  III) and permitted a 2.6-fold induction of luciferase activity when the cells were transfected with LXR␣/RXR␣ and treated with T0901317 ( Figure 3E ). To further address the functionality of the LXRE1, 2 copies of the element were cloned in front of a thymidine kinase promoter. As shown in Figure 3F , a strong 10-fold induction of the transcriptional activity of the construct was observed after LXR␣ and RXR␣ transfection and activation with T0901317, whereas the activity of the basic vector was induced by less than 2-fold ( Figure 3F ).
LXR Activation Enhances RAR␣ Target Gene Expression
To assess whether RAR␣ upregulation by LXR agonist could affect the expression of RAR␣ target genes, we performed microarray analyses in monocytes treated for 24 hours with T0901317 and then for 24 hours with the specific RAR␣ agonist AM580. These experiments suggested that the LXR agonist could enhance AM580-mediated induction of at least 15 genes (Online Table II ). To validate these results, we performed quantitative PCR analysis of genes known to be induced by all-trans retinoic acid (ATRA) or known to be involved in retinoid metabolism. These included tissue inhibitor of metalloproteinase 1 (TIMP-1), 19 adrenomedullin, 20 retinol dehydrogenase (RDH)12, 21 retinoic acid induced gene 14 (RAI14), 22 integrin ␣6, 21 and tissue TGM2. 23 As expected, AM580 stimulated the expression of all these genes. T0901317 treatment alone had no significant effect on TIMP-1, adrenomedullin, RDH12, and integrin ␣6 mRNA levels but stimulated the expression of TGM2 and RAI14. Most importantly, the AM580/ T0901317 combination increased all the tested mRNA levels with a synergistic effect ( Figure 4A ). The specific RAR␣ inhibitor Ro41-5253 partially reversed the effect of the combination treatment ( Figure 4A ). Interestingly Ro41-5253 interfered with the ability of T0901317 to enhance TGM2 and RAI14 mRNA expression, suggesting that the effect of LXR agonist on these genes was at least partially mediated by RAR␣ induction ( Figure 4A ). The highest synergistic effect of AM580 and T0901317 was observed for TGM2 gene, whose expression was induced by more than 50-fold with the combined drugs. A similar effect was observed with the natural RAR agonist ATRA ( Figure 4B ). As assessed by immunoblot, TGM2 protein also accumulated in monocytes exposed to the AM580/ T0901317 combination, whereas it did not with AM580 or T0901317 alone ( Figure 4C ). The synergistic effect of T0901317 and AM580 on TGM2 gene and protein expression observed in monocytes was confirmed in macrophages exposed for 24 hours to T0901317 (1 or 10 mol/L) and then for 24 hours to AM580 (10 or 100 nmol/L) ( Figure 5A and 5B). Silencing of RAR␣ gene ( Figure 5C , top) reduced the effect of LXR agonist, alone or in combination with AM580, on TGM2 expression ( Figure 5C, bottom) . This experiment strongly suggests that the effects of LXR activation on TGM2 are attributable to an increase of RAR␣ levels. Finally, and as expected, the silencing of LXR␣/␤ (previously shown to interfere with T0901317 mediated RAR␣ induction) also abolished the increase in TGM2 induced by the combined treatment ( Figure 5D ). 
LXR and RAR␣ Ligands Are Present in Human Atherosclerotic Plaques at Sufficient Concentration to Regulate TGM2 Expression
To gain insights into the physiological relevance of these observations, we determined whether ATRA, the physiological RAR␣ activator, was present at sufficient concentrations in vivo to regulate TGM2 expression. For that purpose, we collected samples of human atherosclerotic plaques from subjects undergoing carotid endarterectomy and ATRA was quantified in these samples by LC-MS ( Figure 6A ). ATRA was retrieved in all samples at significant concentrations, ranging from 0.2 to 1.4 ng/mg sample (Ϸ1 to 4 mol/L). Although we did not directly measure the levels of side chain hydroxylated sterols, oxidized derivatives of choles- terol, such as 7␤-hydroxycholesterol, were also detected in atherosclerotic plaques ( Figure 6A ). The detection of ATRA and oxidized sterols in plaques led us to assess whether plaque extracts could regulate LXR and RAR target genes in vitro ( Figure 6B ). These extracts induced the expression of LXR targets, such as RAR␣ and ABCG1, and also markedly increased the expression of TGM2, suggesting that the LXR/RAR pathway was efficiently stimulated by endogenous compounds present in atherosclerotic plaques.
TGM2 Induction by LXR/RAR␣ Agonists Improves Macrophage Phagocytosis
It has been reported that macrophages from TGM2 KO mice demonstrated a markedly decrease in their capacity to phagocyte apoptotic cells, a process also known as efferocytosis. 24, 25 Based on this observation, we checked whether TGM2 induction by LXR and RAR␣ agonists could affect the ability of macrophages to phagocyte apoptotic cells. As shown in Figure 7A , AM580 alone had little effects on phagocytosis, whereas T0901317 induced a 50% increase at the highest concentration (10 mol/L). Strikingly, the AM580/T0901317 combination treatment significantly improved phagocytosis efficiency as compared to AM580 or T0901317 alone. Exposure of cells to RAR␣ inhibitor Ro41-5253, or to the TGM2 inhibitors monodansyl-cadaverine or cystamine, or silencing of LXR␣/␤, RAR␣, or TGM2 before the phagocytosis assay all markedly reduced the phagocytosis capacity of T0901317 and T0901317/AM580-stimulated macrophages (Figure 7B, 7C, and 7D ). All of these results argued for a RAR␣/TGM2-dependent effect of LXR agonists on macrophage efferocytosis. 
Discussion
We demonstrate here that, in human monocytes and macrophages, activation of LXRs enhances RAR␣ expression and activity. We show that LXRs interact with a functional LXRE on RAR␣ promoter activity, which establishes RAR␣ as a direct target of LXR. The combination of LXR and RAR agonists has a synergistic effect on some RAR␣ target genes. One of these is TGM2, whose increased expression enhances the capacity of macrophage to engulf apoptotic bodies. These effects were observed at ATRA and LXR agonist concentrations found in human atherosclerotic plaques, which indicates the physiological relevance of LXR synergy with RAR␣ to promote phagocytosis by macrophages ( Figure 8 ). Most LXR-regulated genes described to date are involved in lipid metabolism and inflammation. Three nuclear receptors had been identified as LXR targets. 12, 13, 26 LXR␣ stimulates its own promoter through an autoamplification loop. 12 LXR agonists also stimulate PPAR␥, which favors adipocyte differentiation, 13 and PPAR␥ controls LXR␣ expression in macrophages, which indicates a complex interaction between these 2 genes. 27 More recently, the receptor Rev-Erb␣ was identified as a LXR target in human macrophages. 26 The present study identifies a fourth nuclear receptor, RAR␣, as an LXR target in monocytes and macrophages.
RARs are activated by retinoids such as ATRA and 9-cis retinoic acid. Each of the 3 RARs, namely RAR␣, RAR␤, and RAR␥, has several splice variants. In response to retinoids, RARs heterodimerize with RXR to modulate the transcription of specific target genes through binding to specific DNA response elements and recruitment of cofactors. RARs exert a wide variety of effects on tissue morphogenesis, cell growth, proliferation, differentiation, and apoptosis. 28 The role of RAR␣ in the regulation of granulopoiesis has been extensively investigated as the alteration of RAR␣ transcriptional activity by its fusion with the promyelocytic leukemia gene blocks granulocytic differentiation and causes acute promyelocytic leukemia. Much less is known about the function of RAR␣ in monocytes and macrophages. We show here that TGM2, TIMP-1, and integrin ␣6 are significantly upregulated by RAR␣ agonists (Figure 4) , indicating that the RAR␣ transcriptional pathway is functional in these cells and that the response to RAR␣ agonists is enhanced when monocytes are pretreated with an LXR agonist, which demonstrates that LXR mediated upregulation of RAR␣ has functional consequences.
The highest identified synergistic effect between RAR and LXR agonists was observed for TGM2. LXR agonists alone upregulated TGM2 to a lesser extent, and this effect was reduced in the presence of a specific RAR␣ antagonist or small interfering (si)RNA targeting RAR␣, which may indicate that the effect of the LXR agonist partially depends on RAR␣. TGMs are a family of enzymes that catalyze the crosslinking between glutaminyl and lysyl residues of 2 protein substrates. 29 Alterations of TGM activity have been described in several human diseases such as neurodegenerative diseases or celiac disease. 29 TGM2 is induced by ATRA in different cell types through an RAR␣-dependent mechanism, 23, 30 which is further demonstrated here in monocytes and macrophages.
TGM2 is highly expressed in monocytes and macrophages, in which it plays a role in the clearance of apoptotic cells, 31 which was confirmed in cells from TGM2-deficient mice. 24, 25 We show here that a combination of LXR and RAR agonists can markedly stimulate the phagocytic capacity of macrophages through a TGM2-dependent pathway (Figure 7) . LXR agonist alone also increases phagocytosis, which could be reversed by an RAR␣ antagonist or with siRNA targeting RAR␣. An RAR␣/TGM2 independent pathway might exist also as ABCA1, a well recognized LXR target gene, stimulates phagocytosis by modulating transbilayer redistribution of phosphatidylserine. 32 Importantly, LXR and PPAR␥, a direct LXR target, 13 increase the expression of retinol and retinal metabolizing enzymes such as RDH10 and retinaldehyde dehydrogenases 1 and 2 (endogenous RAR ligands), 33, 34 which may account for the ability of LXR agonists to improve macrophage phagocytic capacities through TGM2. In turn, LXR can also be activated by RAR␣ through induction of CYP27 enzyme and generation of the endogenous LXR activator 27-hydroxycholesterol cholesterol, 35 which indicates a complex crosstalk between LXR, PPAR␥, and RAR␣.
Recent studies indicate that efficient clearance of apoptotic cells by macrophages contribute to atherosclerotic plaque stability 36 and that expression of TGM2 in mouse macrophages also limits the size of atherosclerotic lesions. 37 The ability of the LXR/RAR␣ combination to stimulate TGM2mediated phagocytic capacities of macrophages may improve this beneficial effect. In an attempt to check this hypothesis in mouse models, we observed that the magnitude of RAR␣ induction by LXR agonists was much lower in mouse than in human macrophages, and we failed to identify a significant effect of RAR/LXR agonist combination on efferocytosis in Figure 8 . Regulation of RAR␣ by LXR and its impact on TGM2 expression and phagocytosis in macrophages. LXR agonists induce RAR␣ expression in monocytes/macrophages through direct binding of LXR/RXR on its promoter. The consequences are the induction of TGM2 and an increased capacity of macrophages to phagocyte apoptotic cells. This effect can be emphasized by the addition of retinoids (at concentrations found in human atherosclerotic plaques). LXR agonists could stimulate TGM2 expression and macrophage phagocytosis through alternative pathways. mouse cells. This observation further illustrates the differential behavior of mouse and human macrophages, especially in the field of nuclear receptor signaling. 4 We then explored the physiological relevance of our observations in humans. RAR␣ and LXR are both expressed in human atherosclerotic plaques, 38 but the availability of their endogenous ligands could have been a limiting factor. The natural LXR activator 27-hydroxycholesterol was detected at high concentration in human atherosclerotic lesions 39 and the presence of RAR activators was also indirectly suggested. 38 By using human samples of atherosclerotic plaques, we demonstrate here that ATRA, the physiological RAR␣ activator, is present at a sufficient concentration in human atherosclerotic plaques to induce the expression of TGM2. The described synergy between LXR and RAR agonists that may operate at the level of human atherosclerotic plaques could also be explored therapeutically to stimulate macrophage phagocytosis in pathological situations in which efficient clearance of apoptotic cells by phagocytes prevents the release of potentially toxic or immunogenic molecules from dying cells, ie, in autoimmune diseases. 40 
